GSK at Oncology Medical Congress 2023
This June, at the American Society of Clinical Oncology® (ASCO®) annual meeting, 33 data presentations will describe new findings and progress in our oncology portfolio and pipeline. The presentations at this medical congress will underscore our commitment to maximising patient survival and improving outcomes by developing transformative medicines for people with blood and gynaecologic cancers and also other solid tumours.
Our research into new therapeutic approaches that target key pathways and maximise anti-tumour activity drives our strong oncology pipeline and clinical trial programme, now with 12 assets in development.
Our therapies utilise immuno-oncology, synthetic lethality and tumour cell targeting to expand options for patients in an effort to improve outcomes and quality of life for people with cancer. We are exploring new treatment approaches for our currently marketed medicines, both used alone and in combination, that have the potential to address some of the biggest challenges in oncology. Further, we have the leading portfolio of antibodies targeting checkpoints on the CD226 axis, a promising new area of focus for the next generation of immuno-oncology therapies.
If you are a healthcare professional, you can learn more about our marketed products by selecting your market and the specific GSKPro website on our worldwide directory.
Endometrial Cancer - Andrea’s story
After an endometrial cancer diagnosis six days before her wedding, Andrea went on to fulfil goals of traveling and earning a Master’s degree. Andrea’s advocating for open dialogue about this disease for patients in Singapore and beyond.
Multiple Myeloma - Peter’s story
Cancer can be a taboo topic in Asia. After his multiple myeloma diagnosis, Peter overcame this stigma by sharing his story and leading a community of patients to discuss and support each other through their disease journeys.
Myelofibrosis - Sole2Soul
We’re helping support patients and raise awareness for myelofibrosis, a chronic blood cancer. Learn more from the inaugural Sole2Soul for MPN hike.
Targeting a better future for multiple myeloma patients
GSK is driving progress for the multiple myeloma community by identifying and accelerating innovative solutions. Now in its second year, GSK’s Target the Future Think Tank Challenge awards funding to an individual or group with the most innovative idea to address the unmet needs of people with multiple myeloma. The inaugural grant recipient in 2022 – HealthTree Foundation – is utilising Target the Future funding and GSK resources to improve access, education, and support for underserved communities and minority patients. This year, we’re targeting disparities presently affecting multiple myeloma care and look forward to supporting ideas to address unmet needs.
We are currently accepting grant applications for the 2023 Think Tank Challenge. Find out more about your eligibility and submit your application at our Target the Future site.
Go behind the science
Discover how we’re uniting technology, science, and talent to get ahead of cancer and advance a new generation of cancer therapies.